Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-α

Rheumatology

Volumn 41, Issue 6, 2002, Pages 638-642

  den Broeder, A A ^a   Creemers, M C W ^a   van Gestel, A M ^a   van Riel, P L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adalimumab; Anti TNF ; DAS28; Dose titration; Infliximab; RA

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; D2E7; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; HUMAN; LONG TERM CARE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT;

EID: 0036274348     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/41.6.638     Document Type: Article

References (19)

1. The relative toxicity of disease-modifying antirheumatic drugs
2. Biologic agents for treating rheumatoid arthritis. Concepts and progress
3. Recapitulation of the round-table discussion-assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis
4. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
5. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
6. Long term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis
7. Infliximab and methotrexate in the treatment of rheumatoid arthritis
8. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy
9. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody
10. Invasive pulmonary aspergillosis associated with infliximab therapy
11. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
12. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts
13. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis
14. How does one assess early rheumatoid arthritis in daily clinical practice?
15. Clinical quality management in rheumatoid arthritis: Putting theory into practice
16. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis
17. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo
18. A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis
19. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis